



ISLHD CANCER CLINICAL TRIALS

Illawarra Cancer Care Centre

June 2024

ISLHD CANCER CLINICAL TRIALS UNIT

**Illawarra Cancer Care Centre
Wollongong Hospital**

**Loftus Street
Wollongong NSW 2500**

Ph: 02 4253 4384

Fax: 02 4222 5085

**Email: ISLHD-
CancerClinicalTrials@health.
nsw.gov.au**

The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.

Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Breast cancer
- Colorectal cancer
- Lung cancer
- Pancreatic cancer
- Gynaecological neoplasms
- Prostate cancer
- Skin cancer

REFERRAL OR CONSULTATION

To discuss your patient with an ISLHD Oncology Trials Clinician, please phone the Illawarra Cancer Care Centre on
02 4222 5200

ISLHD Cancer Clinical Trials

CURRENTLY OPEN FOR RECRUITMENT

Scan the QR Code for more information including eligibility criteria

Breast

EXPERT: A randomised Phase III trial of adjuvant radiation therapy versus observation following breast conserving surgery and endocrine therapy in patients with luminal A early breast cancer.

Dr Fox
Jo Boynton



TUGETHER: A phase II, two-arm non-comparative, multi-centre study of tucatinib (ONT-380), pembrolizumab (MK-3475) and trastuzumab in patients with pre-treated advanced HER2-positive breast cancer.

Dr Kasherman
Tia Summer-
side



CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease.

****Opening soon****

Dr Kasherman
Tia Summer-
side



GI/Biliary

OXTOX: Can oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study.

Prof Chantrill
Tia Summer-
side



Neo-IMPACT: A Phase 2 study to evaluate the feasibility and safety of combining modified Folfirinox (mFolfirinox) with durvalumab (MEDI4736) in patients with resectable or borderline resectable pancreatic adenocarcinoma.

****slots by request only****

Prof Chantrill
Tia Summer-
side



GU

NINJA: Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation for patients with intermediate or low-high risk prostate cancer.

Prof Miller
Elise Cardoso



Skin

C-POST: A randomised, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.





A/Prof Brungs
Angela Muir



ISLHD Cancer Clinical Trials

CURRENTLY OPEN FOR RECRUITMENT

Scan the QR Code for more information including eligibility criteria

| | | | |
|----------------------|--|----------------------------------|---|
| Gynae | PARAGON2: Phase II basket study of an ARomatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms. **Cohorts A, B, D, E, F (limited spots) only** | Dr Kasherman Angela Muir |  |
| Solid Tumours | CIBI129A101: A Phase 1/2 Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors. | Dr Brungs Vaniesa Boneham |  |
| Lung | MODERN-LUNG: Phase 2 Study of a moderately hypofractionated schedule of chemoradiation followed by immunotherapy for unresectable locally advanced non-small cell lung cancer. | Dr Gandhidasan Tia Summerside |  |
| | 177Lu-RAD204: Phase 0/I Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radio-labelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Non-small Cell Lung Cancer. | A/Prof Brungs Yi-Shun Chiu |  |

For further information regarding these trials at the Illawarra Cancer Care Centre you may also contact the dedicated trial coordinator as listed or email ISLHD-OncologyTrials@health.nsw.gov.au

| Trial Coordinator | Availability | Contact details |
|---------------------------------|---------------------|------------------------------------|
| Kim Bate (Team Leader-Oncology) | Mon-Fri | Kim.Bate@health.nsw.gov.au |
| Tia Summerside | Mon-Fri | 02 4253 4935 |
| Yi-Shun Chiu | Mon-Fri | YiShun.Chiu@health.nsw.gov.au |
| Vaniesa Boneham | Mon-Fri | 02 4222 5738 |
| Victoria Cosatto | Mon-Fri | Victoria.Cosatto@health.nsw.gov.au |
| Angela Muir | Mon-Thurs | 02 4222 5229 |
| Elise Cardoso | Mon-Thurs | Elise.Cardoso@health.nsw.gov.au |
| Jo Boynton | Tues-Wed | 02 4222 5739 |

